EXPAND TO SEE ALL ALLERGAN BRANDS +

Important Safety Information Patient Safety Information + Directions for use + FOR US PATIENTS Contact Us Set up Account

Product Information Training Practice resources Ordering Rewards Results

Read More +

JUVÉDERM^® INJECTABLE GEL FILLERS INDICATIONS

The JUVÉDERM^® Collection of Fillers includes JUVÉDERM VOLUMA^® XC, JUVÉDERM VOLLURE™ XC, JUVÉDERM^® Ultra Plus XC, JUVÉDERM^® Ultra XC, and JUVÉDERM VOLBELLA^® XC. JUVÉDERM VOLUMA^® XC is for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related mid-face volume deficit in adults over the age of 21. JUVÉDERM VOLLURE™ XC, JUVÉDERM^® Ultra Plus XC, and JUVÉDERM® Ultra XC are for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). JUVÉDERM® Ultra XC is also for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVÉDERM VOLBELLA^® XC is for injection into the lips for lip augmentation and for correction of perioral rhytids in adults over the age of 21.

tailored Treatment for
LIPS and perioral lines

tailored Treatment for
LIPS

JUVÉDERM VOLBELLA® XC is the first and only filler FDA approved to increase lip fullness and correct perioral lines for up to 1 year.1,*

SEE THE DIFFERENCE

Michelle, 30s

BEFORE

AFTER 1 MONTH

BEFOREAFTER

ZOOM

Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.2 mL of JUVÉDERM VOLBELLA® XC was injected into the lips (vermilion body and philtral columns) for lip augmentation.

Bridgham, 20s

BEFORE

AFTER 1 MONTH

BEFOREAFTER

ZOOM

Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.1 mL of JUVÉDERM VOLBELLA® XC was injected into the oral commissures and lips (vermilion body, vermilion border, Cupid’s bow, and philtral columns) for lip augmentation.

Jodi

BEFORE

AFTER 1 MONTH

BEFOREAFTER

ZOOM

Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.15 mL of JUVÉDERM VOLBELLA® XC was injected into the oral commissures and lips (vermilion body, vermilion border, Cupid's bow, and philtral comumns) for lip augmentation, and into the perioral lines.

Tammy, 50s

BEFORE

AFTER 1 MONTH

BEFOREAFTER

ZOOM

Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.05 mL of JUVÉDERM VOLBELLA® XC was injected into the oral commissures and lips (vermilion body, vermilion border, Cupid's bow, and philtral comumns) for lip augmentation, and into the perioral lines.

Sherilee, 50s

BEFORE

AFTER 1 MONTH

BEFOREAFTER

ZOOM

Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.8 mL of JUVÉDERM VOLBELLA® XC was injected into the oral commissures and lips (vermilion body, vermilion border, Cupid's bow, and philtral comumns) for lip augmentation, and into the perioral lines.

These photos are not of a clinical trial subject.

SEE THE DIFFERENCE

Clancy, 30s

BEFORE

AFTER 1 MONTH

AT 1 YEAR

BEFOREAFTER

ZOOM

Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment, 1 month after treatment, and 1 year after treatment. A total of 1.2 mL of JUVÉDERM® Ultra XC was injected into the oral commissures and lips (vermilion body and vermilion border) for lip augmentation.

Alicia, 40s

BEFORE

AFTER 1 MONTH

BEFOREAFTER

ZOOM

Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 1.5 mL of JUVÉDERM® Ultra XC was injected into the oral commissures and lips (vermilion body and vermilion border) for lip augmentation.

These photos are not of a clinical trial subject.

‡ Patients reported improvement in satisfaction with their lips based on the Satisfaction With Lips module of the FACE-Q questionnaire. They reported improvement in satisfaction with their lip lines based on the Satisfaction With Lip Lines module of the FACE-Q. At each study visit, responses on each module generated a score ranging from 0 to 100. Improvement was defined as a higher score versus baseline.3

†Patients rated the natural look of their lips on an 11-point scale, where 0 = unnatural looking and 10 = natural looking. Patients rated the natural feel of their lips on a separate 11-point scale, where 0 = unnatural feeling and 10 = natural feeling. The percentages here reflect patients who reported a rating of 7 to 10 on each scale.3

‡Versus baseline. Patients rated their satisfaction on an 11-point scale, where 0 = very dissatisfied and 10 = very satisfied.4

†Versus baseline. Based on responses to a 14-item assessment of the look and feel of their lips and mouth area.4

References: 1. JUVÉDERM VOLBELLA® XC Directions for Use, 2017. 2. JUVÉDERM VOLBELLA® XC Patient Labeling, 2016. 3. Data on file, Allergan, May 29, 2015; CSR JUVÉDERM VOLBELLA® XC-004 Final Report. 4. Data on file, Allergan, July 7, 2016; Perioral Lines Satisfaction at 3 Months.

JUVÉDERM^® INJECTABLE GEL FILLERS INDICATIONS

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.

WARNINGS

•Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, inject the product slowly and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur
•Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled

PRECAUTIONS

•In order to minimize the risk of potential complications, these products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy
•Healthcare professionals are encouraged to discuss the potential risks of soft-tissue injections with their patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications
• The safety and effectiveness for the treatment of anatomic regions other than the mid-face with JUVÉDERM VOLUMA^® XC; facial wrinkles and folds with JUVÉDERM^® Ultra XC, JUVÉDERM^® Ultra Plus XC, and JUVÉDERM VOLLURE™ XC; and the lips and perioral area with JUVÉDERM^® Ultra XC and JUVÉDERM VOLBELLA^® XC have not been established in controlled clinical studies
•As with all transcutaneous procedures, dermal filler implantation carries a risk of infection. Follow standard precautions associated with injectable materials
•The safety for use during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied
•The safety for use of JUVÉDERM VOLUMA^® XC in patients under 35 or over 65 years, JUVÉDERM^® Ultra XC and JUVÉDERM^® Ultra Plus XC in patients under 18 years, and JUVÉDERM VOLLURE™ XC and JUVÉDERM VOLBELLA^® XC in patients under 22 years has not been established
•Use with caution in patients on immunosuppressive therapy
•Patients who are using products that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites
•If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or if these products are administered before the skin has healed completely, there is a possible risk of an inflammatory reaction at the treatment site
•Patients who experience skin injury near the site of implantation may be at a higher risk for adverse events
•The safety of JUVÉDERM VOLUMA^® XC injectable gel for use in patients with very thin skin in the mid-face has not been established
•Patients may experience late onset nodules with use of dermal fillers, including JUVÉDERM VOLUMA^® XC
•Patients may experience late onset adverse events with use of dermal fillers

ADVERSE EVENTS

The most commonly reported side effects for JUVÉDERM^® injectable gels were injection-site redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM VOLBELLA^® XC, dryness was also reported. For JUVÉDERM VOLUMA^® XC, side effects were predominantly moderate in severity, with duration of 2 to 4 weeks; for JUVÉDERM^® Ultra XC, JUVÉDERM^® Ultra Plus XC, or JUVÉDERM VOLLURE™ XC, they were mostly mild or moderate in severity, with duration of 14 days or less; and for JUVÉDERM VOLBELLA^® XC, they were predominantly mild or moderate, with duration of 30 days or less.

To report an adverse reaction with any product in the JUVÉDERM^® Collection, please call Allergan at 1-800-433-8871. Please visit JuvedermDFU.com for more information.

Products in the JUVÉDERM® Collection are available by prescription only.